• Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
131
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Registered pharmaciesand medicines relatedregulatory issuesHugh SimpsonDirector of Policy and Communications
  • 2. Update on MHRA’s human medicineslegislation consolidation• Timetable• What we have done• Section 10(7)• Optimisation of medicines use• Next steps
  • 3. REGISTERED PHARMACIES UPDATE
  • 4. Contents1. Context and approach2. Licensed medicines3. Extemporaneous preparation of (unlicensed) methadone4. Manufacturing by registered pharmacies5. Supervision of the sale of Pharmacy ‘P’ category medicines
  • 5. Context and approach1. Development of new standards (and new inspection model) has enabled us to take a fresh look at a range of medicines related issues2. Focus on patient safety, principle-based approach and the need to be consistent with wider regulatory and legal frameworkPrinciple based approach:• Council’s vision and strategy• Our policy in relation to standards setting• Consistent with the legal framework• That we need to consider the role of others
  • 6. Licensed medicines - background• Directive 2001 /83/EC on medicinal products for human use• GPhC interim standards based on RPSGB policy• General Medical Council guidance – update and position of MHRA• Novartis Judicial Review of the NHS in relation to use of Avastin
  • 7. Licensed medicines – ad hoc groupdiscussions• We have to be consistent with the legal position in Directive 2001/83/EC on medicines for human use• It is not for the GPhC to allow ‘exemptions’ to law• As it is not a GPhC standard, but interpretation of the law, our position could sit outside our standards but would need to be explicit• We need to ensure consistency, where possible, with the GMC and other regulators
  • 8. Statements for consideration1. The direction of travel would mean that a GPhC position on supply of licensed medicines should not be set out in standards2. We would need to provide clear and unequivocal guidance to registrants about the legal position and how to meet our (professional) standards3. Given the forthcoming judicial review and legal advice received by the GMC, we should ensure that we are consistent with the legal interpretation and any high court decisions
  • 9. Extemporaneous preparation -background• Longstanding ‘exemption’ in RPSGB standards adopted on an interim basis by the GPhC• Extemporaneously prepared methadone is an unlicensed medicine• Call for evidence issued to understand better motivation and practice (rather than consult on proposition)
  • 10. Extemporaneous preparation – ad hocgroup discussions• Consensus view that neither RPSGB nor GPhC could provide an ‘exemption’ to the law• Directive seems explicit that only exceptions to supplying medicines with a marketing authorisation are where one is not available or where there is a ‘special need’• Need to consider impact and timing of change, but not appropriate to allow something which goes against legal framework
  • 11. Statements for consideration1. If cost is not an acceptable reason for supplying unlicensed medicines, the GPhC would need to be explicit that extemporaneous preparation is not consistent with the law2. If the practice is deemed inconsistent with law and our standards we would need to commission/carry out research to ascertain the scale of the practice and have a reasonable implementation timetable
  • 12. Manufacturing by registeredpharmacies - background• Medicines can only be manufactured/prepared by holders of appropriate licences (Medicines Act 1968)• S10 exempts pharmacists from a registered pharmacy (and some other settings such as hospitals) enabling preparation against a prescription for a named patient• Challenge has been at an operational level with confusion arising when registered pharmacies also holding a manufacturers/specials licence from MHRA
  • 13. Manufacturing by registeredpharmacies – ad hoc group discussions• Noted discussions executive have had with MHRA• Not an issue about size/volume – about preparation against a prescription for a named patient.• Some early discussions for a new protocol at operational level where MHRA license holder claims to be working under a s10 exemption
  • 14. Statements for consideration1. We need to pursue clear and consistent communication from ourselves and the MHRA2. Operational protocols should be developed to ensure joint decision making can take place consistent with the legal and policy positions of MHRA and GPhC3. Ultimately it is for the licensor (MHRA) to determine whether a registered pharmacy requires a manufacturers licence.
  • 15. Supervision of the sale of Pharmacy ‘P’category medicines - background• Pharmacy medicines must be sold under the supervision of a pharmacist from a registered pharmacy (Medicines Act 1968)• The GPhC adopted, as an interim measure, the standard that P medicines cannot be made available for self selection• Our consultation set out a desire to be outcome focussed and encourage pharmacists to use their professional judgement• Current categorisation process for medicines not explicit about the influence of the ‘professional’ interpretation supervision in the registered pharmacy context
  • 16. Supervision of the sale of ‘P’ medicines– ad hoc group discussions• Heard strong opinions from representative bodies and from some of the patient/public participants• Broad agreement within ad hoc group that it should be the owner/superintendent who decides how best to fulfil legal requirements of supervision in this context• Some discussion about the need for professional leadership bodies in provide advice to their members/profession
  • 17. Statements for consideration1. Models of delivery and supervision have changed in pharmacy and will continue to do so; we should maintain and focus on outcomes in relation to supply of P category medicines2. Our inspection model should take into account, and we should communicate, the sorts of risk assessment and decision making processes we think owners and SI’s should undertake before allowing any self- selection